Australia News
Filter News
Found 6,497 articles
-
AdAlta raises $5 million and announces entitlement offer to raise up to a further $2 million
5/23/2019
AdAlta Limited (ASX: 1AD) is pleased to announce the placement of up to 33,333,333 fully paid ordinary shares in the Company to sophisticated and institutional investors at a price of $0.15 per share to raise $5 million (before costs) (Placement).
-
Sorilux was approved for the treatment of patients age 12 and up.
-
Longas Technologies: Morphoseq™ Novel DNA Sequencing Technology Enables Highly Accurate and Cost Effective Long Read Sequencing on Short Read NGS Platforms
5/22/2019
Professor Aaron Darling presented at ‘Sequencing, Finishing and Analysis in the Future’ meeting, May 21 – 23, Santa Fe, NM, USA
-
FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis
5/22/2019
Mayne Pharma Group Limited is pleased to announce that the US Food and Drug Administration has approved SORILUX® Foam, 0.005% in adolescents.
-
Technology mix the key to unlocking enzyme dynamics
5/22/2019
Australian researchers have used a unique combination of cutting-edge technologies to discover a biochemical mechanism fundamental to life.
-
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
5/20/2019
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer research network sponsored by the National Cancer Institute.
-
New Study Published in Journal of Breast Imaging Validates Volpara®Density™ in Tyrer-Cuzick Breast Cancer Risk Model
5/20/2019
Research has demonstrated that the use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification and could be used to help guide personalized medicine through risk-adapted screening.
-
Global Biotechnology and Venture Capital Executive Joins Imugene Board
5/20/2019
Dr. Eckstein recently joined Apollo Ventures as Managing Partner.
-
Saluda Medical Announces New 3-Month, 12-Month and 18-Month Data Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System to be Presented at 14th INS World Congress
5/20/2019
11 Presentations - Including 4 Plenary Presentations - to Feature the Evoke System
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
BioSpace Global Roundup, May 16
5/16/2019
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more. -
Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology
5/16/2019
Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its Morphoseq™ technology and announcing the appointment to CEO of Nick McCooke, who built and led the team at Solexa that pioneered NGS prior to the company being acquired by Illumina.
-
Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System
5/16/2019
AVITA Medical announced that the health economic model of the U.S. burn care pathway, developed in collaboration with Biomedical Advanced Research and Development Authority (BARDA) and IQVIA, has been published in the peer-reviewed journal, Advances in Therapy.
-
ImpediMed’s Positive Interim Study Results Give Hope to Millions of Breast Cancer Survivors
5/16/2019
Professor Sheila Ridner, PhD, RN, FAAN, the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing, Principal Investigator, PREVENT trial.
-
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
5/15/2019
NeuClone Pharmaceuticals Ltd. announced it will initiate the Phase I clinical trial of its Stelara® biosimilar in the second half of 2019.
-
AVITA Medical Appoints Interim CFO
5/15/2019
AVITA Medica announced that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately.
-
George Clinical Awarded Taiwanese Drug License
5/15/2019
New Status Enhances Clinical Trial Options in the Country
-
SpeeDx Receives Clearance for PlexPCR Respiratory Virus Test
5/13/2019
Highly multiplexed test offers workflow advantages to support the Flu season surge
-
New positive data from phase IIa trial in brain cancer patients
5/9/2019
With one month to go until World Brain Tumour Day on June 8, Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce new safety data from its ongoing phase IIa study of GDC-0084 in newly-diagnosed patients with glioblastoma.
-
EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy
5/9/2019
EnGeneIC Limited announced that the first four patients have been dosed in a Phase 1/2a study using the Company's tumor-targeting, immunogenic EDVs™ to deliver a cytotoxic drug payload directly to tumors of patients who have exhausted curative treatment options.